Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $146.68M
• Dividend Yield: N/A
• Average Volume (3M): 5.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 239.92%
• EPS Growth: 79.41%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 245,401,980
• 10 Day Avg. Volume: 5,664,943
• 30 Day Avg. Volume: 5,406,690
• PEG Ratio: -0.05
• Price to Book (P/B): 21.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.61
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.63
• Enterprise Value/Gross Profit: 1.92
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $4.10
• Price Target Upside: 583.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 49 Neutral
• Price Target: $0.50 ▼(-16.67%Downside)

Sangamo Biosciences' overall stock score is driven by its significant financial struggles, as reflected in the financial performance score. While there are promising developments in collaborations and clinical trials, immediate financial challenges and a negative P/E ratio weigh heavily on the stock's attractiveness. The technical analysis indicates potential short-term volatility, and recent corporate events suggest both strategic progress and regulatory risks.

Positive Factors

Clinical Trials

The updated 1-year eGFR slope data with all patients continues to look encouraging, maintaining superiority over published data for other drugs.

Financial Stability

Recent financings have extended the company’s runway into late 3Q25, aligning Sangamo’s pipeline, platform, and execution to unlock meaningful upside from current levels.

Strategic Partnerships

Sangamo's STAC-BBB platform has secured three high-value partnerships with Genentech, Astellas, and Eli Lilly, with further collaborations anticipated.

Negative Factors

Development Risks

Risks include clinical development risk tied to isa-vec, commercialization risk, and reimbursement risk among others.

Regulatory Challenges

The upcoming pivotal data readout from the STAAR trial in Fabry disease could be a major de-risking event, potentially leading to first-in-class gene therapy approval.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo Therapeutics generates revenue through a combination of collaborative partnerships, licensing agreements, and government grants. The company forms strategic alliances with major pharmaceutical firms, such as Pfizer and Biogen, to co-develop and commercialize its genomic therapies, often receiving upfront payments, milestones, and royalties as part of these collaborations. Additionally, Sangamo licenses its proprietary technology to other biotech firms, thereby earning licensing fees. Government and institutional grants contribute to funding specific research projects, enhancing the company's ability to advance its therapeutic programs. These diverse streams of income collectively support Sangamo's business operations and ongoing research initiatives.

Sangamo Biosciences Financial Statement Overview

Summary

Sangamo Biosciences is experiencing severe financial instability with declining revenue, a strained balance sheet, and persistently negative cash flows, indicating significant operational risks.

Income Statement

Sangamo Biosciences has shown significant volatility in its revenue and profitability metrics. There has been a substantial decline in total revenue from $176.23M in 2023 to $57.8M in 2024, representing a negative revenue growth trend. Gross profit margins have been inconsistent, and the company consistently reports negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet reflects a strained financial position with a declining equity base, from $82.89M in 2023 to $22.77M in 2024. The debt-to-equity ratio has worsened due to reduced equity, suggesting increased leverage. The equity ratio declined significantly, indicating reduced shareholder equity relative to total assets, potentially increasing financial risk.

Cash Flow

The cash flow statements highlight persistent negative free cash flow, with a slight improvement from -$246M in 2023 to -$67.4M in 2024. Operating cash flow has remained negative, raising concerns about the company's ability to generate cash from operations. The free cash flow to net income ratio remains unfavorable, reflecting poor cash conversion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	57.80M	-45.33M	99.19M	101.26M	-62.45M
EBITDA	-89.09M	-87.43M	-189.17M	-173.90M	-123.87M
Net Income	-97.94M	-257.83M	-192.28M	-178.30M	-121.12M
Balance Sheet
Total Assets	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	41.92M	81.00M	277.63M	464.72M	691.95M
Total Debt	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	22.77M	82.89M	294.96M	375.34M	497.37M
Cash Flow
Free Cash Flow	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.50, and below the 200-day MA of 1.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.92 is Neutral, neither overbought nor oversold. The STOCH value of 57.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
SGMO	49 Neutral	$146.68M	―	-262.12%	―	239.92%	79.41%
FDMT	46 Neutral	$213.56M	―	-32.97%	―	―	―
IKT	46 Neutral	$137.53M	―	-79.02%	―	-100.00%	38.72%
TERN	45 Neutral	$529.27M	―	-32.12%	―	―	10.98%
ANNX	38 Underperform	$279.77M	―	-66.13%	―	―	43.21%
ELTX	30 Underperform	$156.93M	―	-744.59%	―	―	27.65%

Sangamo Biosciences Corporate Events

Sangamo Announces Positive Results for Fabry Disease Therapy

On June 24, 2025, Sangamo Therapeutics, Inc. announced positive topline results from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed significant improvements in kidney function and quality of life measures, with a favorable safety profile. These results support the potential of isaralgagene civaparvovec as a one-time treatment for Fabry disease, paving the way for a Biologics Licensing Application under the Accelerated Approval pathway by early 2026.

The most recent analyst rating on (SGMO) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Approves Amendments to Equity Plan

On June 12, 2025, Sangamo Therapeutics, Inc. held its annual meeting where stockholders approved significant amendments to the 2018 Equity Incentive Plan. This included increasing the number of shares available for issuance and the number of shares for incentive stock options. The meeting also saw the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the company’s independent auditor. These decisions reflect Sangamo’s strategic focus on expanding its equity incentives to attract and retain talent, which could enhance its competitive position in the biotech industry.

The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Announces $23 Million Share Offering

On May 12, 2025, Sangamo Therapeutics announced an underwriting agreement with Cantor Fitzgerald & Co. for the issuance and sale of shares and warrants, aiming to raise approximately $23 million. This offering, expected to close on May 14, 2025, is part of Sangamo’s strategy to bolster its financial position, potentially impacting its market presence and stakeholder interests.

The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Receives Nasdaq Deficiency Notice

On April 30, 2025, Sangamo Therapeutics, Inc. received a deficiency notice from Nasdaq due to its common stock’s bid price closing below $1.00 per share for 30 consecutive business days, which is below the required minimum for continued listing. The company has until October 27, 2025, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least 10 consecutive business days. If compliance is not achieved by then, Sangamo may qualify for an additional 180-day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to resolve the issue, potentially through a reverse stock split. Failure to comply could result in delisting, though the company can appeal such a decision.